LFMD Stock Risk & Deep Value Analysis
LifeMD Inc
Healthcare • Health Information Services
DVR Score
out of 10
What You Need to Know About LFMD Stock
We analyzed LifeMD Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LFMD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
LFMD Risk Analysis & Red Flags
What Could Go Wrong
Despite significantly improved liquidity with $36.8M cash and an undrawn $50M credit facility, LifeMD still operates with a GAAP net loss and guides for an adjusted EBITDA loss in Q1 2026. If customer acquisition costs in the highly competitive GLP-1 market remain elevated or revenue growth decelerates further, the company could continue to burn cash at a rate that necessitates future dilutive capital raises, despite the current runway, which would negatively impact shareholder value.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
High
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Q4 2025 revenue missed consensus estimates.
- ⚠
Q1 2026 adjusted EBITDA guidance projects a loss ($4-$5M) after a positive Q4 2025 ($4.8M).
- ⚠
Highly competitive GLP-1 market requiring significant ongoing marketing spend.
Upcoming Risk Events
- 📅
Q1 2026 revenue or adjusted EBITDA performance below guidance
- 📅
Increased competitive pressure from larger players (e.g., Hims & Hers)
- 📅
Adverse regulatory changes impacting telehealth or GLP-1 prescriptions
When to Reconsider
- 🚪
Quarterly revenue declines or significant deceleration below 10% YoY growth for two consecutive quarters.
- 🚪
Adjusted EBITDA remaining negative for more than three consecutive quarters beyond Q1 2026.
- 🚪
Announced dilutive equity capital raise that materially increases shares outstanding (>10%) while cash runway is still sufficient.
Unlock LFMD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does LifeMD Inc (LFMD) Do?
Market Cap
$211.07M
Sector
Healthcare
Industry
Health Information Services
Employees
304
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company operates through two operating segments: Telehealth and WorkSimpli. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation, and hair loss; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; and Cleared which provides personalized treatments for allergy, asthma and immunology. It also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. Further, it offers GLP-1 for weight management and in-home health monitoring devices. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Visit LifeMD Inc WebsiteInvestment Thesis
LifeMD is a high-growth telehealth company well-positioned in the booming GLP-1 weight management market. Its significantly improved financial health, marked by a robust cash position and undrawn credit facility, provides the necessary runway to scale operations, expand its patient base, and drive towards sustainable profitability. With strong gross margins and an adaptive leadership team, LifeMD has the potential to become a significant player in the digital health sector, offering compelling 10x growth potential within 3-5 years for aggressive investors.
Is LFMD Stock Undervalued?
Unlock the full AI analysis for LFMD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
LFMD Price Targets & Strategy
12-Month Target
$10.00
Bull Case
$15.00
Bear Case
$2.50
Valuation Basis
Based on 2.5x forward P/S applied to estimated FY26 revenue of $220M.
Entry Strategy
Dollar-cost average between $3.50-$4.50, especially on dips towards $3.00 (historical support if available, or psychological level).
Exit Strategy
Take 50% profit at $10.00, reassess at $15.00. Implement a stop loss at $2.80 to protect capital.
Portfolio Allocation
7-10% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is LFMD Financially Healthy?
Valuation
P/E Ratio
16.63
Forward P/E
16.92
EV/EBITDA
13.23
PEG Ratio
29.86
Price/Book
1.87
Price/Sales
1.04
Profitability
Gross Margin
85.70%
Operating Margin
7.80%
Net Margin
6.58%
Return on Equity
-83.93%
Revenue Growth
25.00%
EPS
$-0.25
Balance Sheet
Current Ratio
1.45
Quick Ratio
1.32
Cash & Equivalents
$36.79M
Cash Flow
Operating Cash Flow
$18.00M
Free Cash Flow
$15.00M
EBITDA
$15.30M
Other
Beta (Volatility)
1.44
Does LFMD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is strengthening as LifeMD scales its platform and builds a loyal patient base, but it faces durability challenges due to low barriers to entry in general telehealth and intense competition in the GLP-1 space.
Moat Erosion Risks
- •Aggressive pricing and marketing from larger, well-funded competitors like Hims & Hers.
- •Emergence of new, highly differentiated telehealth platforms.
- •Regulatory changes that could favor traditional healthcare providers or restrict digital health services.
LFMD Competitive Moat Analysis
Sign up to see competitive advantages
LFMD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data provided, but strong growth themes often generate interest)
Institutional Sentiment
Positive (7 Buy, 1 Hold, 1 Sell from 9 analysts; recent H.C. Wainwright PT raise to $10).
Insider Activity (Form 4)
New CFO appointed on 2026-03-16; no specific Form 4 buy/sell transactions reported in the last 90 days.
Options Flow
Normal options activity (no specific data provided).
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Mixed, with a Q4 2025 revenue miss but an EPS beat, suggesting some volatility and investor focus on both top and bottom line trends.
Key Metrics to Watch
Competitive Position
Top Competitor
HIMS
Market Share Trend
Gaining (implied by 25% YoY revenue growth in 2025 in a competitive market).
Valuation vs Peers
Likely trades at a discount to best-in-class telehealth peers like Hims & Hers on a P/S basis, reflecting smaller scale and earlier stage of profitability.
Competitive Advantages
- •Highly scalable direct-to-consumer telehealth platform
- •Strong and improving gross margins (87.1% in Q4 2025)
- •Agility of a smaller company to pivot and innovate quickly
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive LFMD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (estimated May 5, 2026)
- •Continued growth in GLP-1 weight management subscriptions
- •Impact of new CFO on financial operations and strategy
Medium-Term (6-18 months)
- •Expansion into new complementary telehealth therapeutic areas
- •Potential strategic partnerships or M&A activities
- •Achieving consistent positive adjusted EBITDA on a quarterly basis
Long-Term (18+ months)
- •Establishing market leadership in a specialized telehealth niche
- •Sustained GAAP profitability and free cash flow generation
- •Disruption of traditional healthcare models through digital health solutions
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for LFMD?
- ✓
Consistent acceleration in quarterly revenue growth rates.
- ✓
Achievement of positive adjusted EBITDA for multiple consecutive quarters.
- ✓
Evidence of sustained user growth and retention in key therapeutic areas.
Bull Case Analysis
See what could go right with Premium
Competing with LFMD
See how LifeMD Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
LifeMD Inc LFMD | $211.1M | 7.2 | 16.6 | $194.1M | 6.6% | 25.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Hims & Hers Health Inc HIMS | $6.2B | 5.5 | 48.6 | $2.3B | 5.5% | 59.0% | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for LifeMD Inc (LFMD)?
As of March 25, 2026, LifeMD Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of LifeMD Inc?
LifeMD Inc's market capitalization is approximately $211.1M. The company operates in the Healthcare sector within the Health Information Services industry.
What ticker symbol does LifeMD Inc use?
LFMD is the ticker symbol for LifeMD Inc. The company trades on the NGM.
What is the risk level for LFMD stock?
Our analysis rates LifeMD Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of LFMD?
LifeMD Inc currently has a price-to-earnings (P/E) ratio of 16.6. This is in line with broader market averages.
Is LifeMD Inc's revenue growing?
LifeMD Inc has reported revenue growth of 25.0%. The company is showing strong top-line momentum.
Is LFMD stock profitable?
LifeMD Inc has a profit margin of 6.6%. The company is profitable but margins are modest.
How often is the LFMD DVR analysis updated?
Our AI-powered analysis of LifeMD Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for LFMD (LifeMD Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.